X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7695) 7695
Publication (622) 622
Book Review (172) 172
Book Chapter (76) 76
Newsletter (25) 25
Book / eBook (23) 23
Conference Proceeding (14) 14
Dissertation (5) 5
Journal / eJournal (4) 4
Government Document (2) 2
Magazine Article (2) 2
Streaming Video (2) 2
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4708) 4708
index medicus (4063) 4063
animals (2839) 2839
male (2638) 2638
administration, cutaneous (2581) 2581
female (2573) 2573
pharmacology & pharmacy (1500) 1500
dermatology (1387) 1387
adult (1317) 1317
middle aged (1303) 1303
skin (1292) 1292
mice (1154) 1154
oncology (1040) 1040
aged (970) 970
care and treatment (782) 782
treatment outcome (776) 776
rats (775) 775
cancer (754) 754
toxicology (748) 748
cutaneous leishmaniasis (742) 742
melanoma (647) 647
toxicity (621) 621
analysis (605) 605
skin - drug effects (591) 591
skin - metabolism (575) 575
cutaneous melanoma (564) 564
therapy (545) 545
skin absorption (543) 543
in-vitro (531) 531
research (522) 522
immunology (511) 511
health aspects (510) 510
leishmaniasis (500) 500
chemotherapy (491) 491
dose-response relationship, drug (465) 465
skin neoplasms - drug therapy (444) 444
skin neoplasms - pathology (438) 438
aged, 80 and over (432) 432
medicine & public health (423) 423
parasitic diseases (423) 423
adolescent (408) 408
administration, oral (403) 403
drug therapy (382) 382
mice, inbred balb c (380) 380
skin - pathology (363) 363
drug delivery systems (362) 362
leishmaniasis, cutaneous - drug therapy (346) 346
antineoplastic agents - therapeutic use (344) 344
diagnosis (342) 342
risk factors (338) 338
surgery (338) 338
visceral leishmaniasis (333) 333
efficacy (331) 331
drugs (327) 327
time factors (326) 326
transdermal medication (323) 323
permeability (321) 321
immunotherapy (320) 320
child (313) 313
young adult (312) 312
parasitology (303) 303
melanoma - drug therapy (300) 300
article (299) 299
infectious diseases (292) 292
medicine (291) 291
retrospective studies (290) 290
disease models, animal (289) 289
research article (284) 284
medicine, research & experimental (279) 279
double-blind (274) 274
pharmacology/toxicology (274) 274
melanoma - pathology (267) 267
patients (259) 259
antineoplastic agents - adverse effects (252) 252
rats, sprague-dawley (251) 251
nanoparticles (250) 250
chemistry, medicinal (248) 248
biochemistry & molecular biology (245) 245
management (245) 245
prognosis (244) 244
parasites (242) 242
metastatic melanoma (241) 241
metastasis (238) 238
usage (237) 237
apoptosis (234) 234
expression (225) 225
clinical trials (222) 222
review (222) 222
pharmacokinetics (221) 221
hematology (218) 218
infections (218) 218
biomedicine (217) 217
inflammation (217) 217
tumors (214) 214
microbiology (213) 213
radiotherapy (213) 213
in-vivo (210) 210
penetration (210) 210
lymphoma, t-cell, cutaneous - drug therapy (209) 209
t cells (206) 206
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (7) 7
Online Resources - Online (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Bindery (1) 1
Gerstein Science - Periodical Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7637) 7637
French (75) 75
Japanese (65) 65
German (30) 30
Russian (25) 25
Spanish (20) 20
Chinese (13) 13
Polish (12) 12
Korean (9) 9
Portuguese (9) 9
Italian (5) 5
Hungarian (2) 2
Romanian (2) 2
Arabic (1) 1
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Clinical Dermatology, ISSN 1175-0561, 06/2018, Volume 19, Issue 3, pp. 345 - 361
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death... 
CELL LUNG-CANCER | CUTANEOUS ADVERSE EVENTS | UNTREATED MELANOMA | METASTATIC MELANOMA | ANTI-PD-1 THERAPY | IPILIMUMAB THERAPY | PREEXISTING AUTOIMMUNE DISORDERS | JAVELIN SOLID TUMOR | OF-THE-LITERATURE | NIVOLUMAB THERAPY | DERMATOLOGY | Index Medicus
Journal Article
Journal of the National Comprehensive Cancer Network : JNCCN, ISSN 1540-1405, 03/2019, Volume 17, Issue 3, pp. 255 - 289
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events... 
CELL LUNG-CANCER | CUTANEOUS ADVERSE EVENTS | IMMUNE CHECKPOINT INHIBITORS | STAGE-III MELANOMA | ONCOLOGY | INTRAVENOUS IMMUNOGLOBULIN THERAPY | PROGRAMMED DEATH 1 | OPEN-LABEL | ACUTE INTERSTITIAL NEPHRITIS | NIVOLUMAB PLUS IPILIMUMAB | MYCOPHENOLATE-MOFETIL
Journal Article
International Journal of Hematology, ISSN 0925-5710, 11/2019, Volume 110, Issue 5, pp. 519 - 520
Keywords: Toxicity; Chemotherapy; Cutaneous side effects Author Affiliation: (1) grid.8404.8, 0000 0004 1757 2304, Haematology Unit, Careggi... 
Oncology | Chemotherapy | Cutaneous side effects | Medicine & Public Health | Hematology | Toxicity | Cancer
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 02/2016, Volume 30, Issue 2, pp. 250 - 257
Journal Article
Toxicologic Pathology, ISSN 0192-6233, 6/2015, Volume 43, Issue 4, pp. 474 - 481
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 07/2004, Volume 36, Issue 3, pp. 772 - 776
Journal Article
Targeted Oncology, ISSN 1776-2596, 6/2009, Volume 4, Issue 2, pp. 107 - 119
The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors has increased considerably in recent years. Currently, they are... 
Rash | Phosphatase inhibitor | Medicine & Public Health | Menadione | EGFR inhibitor | Skin toxicity | Oncology | Biomedicine general | Epidermal growth factor receptor | CHEMOKINE EXPRESSION | PLUS CETUXIMAB | EGF-RECEPTOR | CELL LUNG-CANCER | SEVERE CUTANEOUS REACTION | PHASE-III TRIAL | SUPPORTIVE CARE | ONCOLOGY | TYROSINE KINASE INHIBITOR | ERLOTINIB | Erlotinib Hydrochloride | Prognosis | Humans | Antibodies, Monoclonal - adverse effects | Head and Neck Neoplasms - physiopathology | Protein Kinase Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - physiopathology | Pancreatic Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized | Exanthema - chemically induced | Exanthema - prevention & control | Quinazolines - administration & dosage | Cetuximab | Patient Education as Topic | Carcinoma, Non-Small-Cell Lung - pathology | Exanthema - physiopathology | Pancreatic Neoplasms - pathology | Head and Neck Neoplasms - drug therapy | Clinical Trials as Topic | Head and Neck Neoplasms - pathology | Vitamin K 3 - administration & dosage | Animals | Antibodies, Monoclonal - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Quinazolines - adverse effects | Quality of Life | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Pancreatic Neoplasms - physiopathology | Medical colleges | Algorithms | Epidermal growth factor | Phosphatases | Pancreatic cancer | Colorectal cancer | Physiological aspects | Skin diseases | Lung cancer, Non-small cell | Clinical trials | Patient education | Index Medicus
Journal Article
Journal Article
Drug Safety, ISSN 0114-5916, 06/2013, Volume 36, Issue 6, pp. 413 - 426
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive... 
FACTOR RECEPTOR INHIBITORS | THYROID-DYSFUNCTION | INDUCED SKIN RASH | DOSE-ESCALATION | SELECTIVE INHIBITOR | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CANCER-PATIENTS | CUTANEOUS TOXICITIES | SUNITINIB INDUCES HYPOTHYROIDISM | ANGIOGENESIS INHIBITORS | COLORECTAL-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Neoplasms - metabolism | Protein-Tyrosine Kinases - metabolism | Skin - metabolism | Humans | Endothelium, Vascular - drug effects | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Endothelium, Vascular - enzymology | Neoplasm Proteins - metabolism | Dose-Response Relationship, Drug | Receptor, Epidermal Growth Factor - metabolism | Receptors, Vascular Endothelial Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Biomarkers - metabolism | Risk Assessment | Neoplasms - enzymology | Evidence-Based Medicine | Skin - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Endothelium, Vascular - metabolism | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Hypertension | Enzymes | Kinases | Hypothyroidism | Proteins | Angiogenesis | Epidermal growth factor | Biomarkers | Ligands | Skin | Pharmaceutical industry | Drug dosages | Cancer | Index Medicus
Journal Article
Progress in Drug Research, ISSN 0071-786X, 2016, Volume 71, pp. 81 - 87
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2013, Volume 69, Issue 3, pp. 463 - 472
Skin toxicities are the most common side effects associated with the epidermal growth factor receptor inhibitor erlotinib, occurring in most patients receiving... 
Dermatology | non-small cell lung cancer | skin toxicities | cutaneous side effects | epidermal growth factor receptor inhibitor | erlotinib | acneiform rash | Japanese patients | prevention